PEPDURA AB

Advancing Peptide Science into Clinical Reality

Call for Non-Confidential Peptide Technology Descriptions

An invitation to academic research groups and technology transfer offices

Deadline June 30, 2026

PURPOSE

Pepdura invites academic scientists to submit brief, non-confidential descriptions of peptide technologies for initial scientific evaluation. This call is intentionally focused: we are not seeking every peptide project, but rather those with a specific profile that aligns with our translational strategy. Submissions require no disclosure of confidential data, proprietary sequences, or unpublished mechanistic detail.

SCIENTIFIC FOCUS — WHAT WE SEEK

We have a defined scientific interest in technologies that combine three elements:

- Structural stabilisation of peptides (stapling, macrocyclisation, backbone modification, or functionally equivalent strategies) to overcome proteolytic instability and improve pharmacokinetic behaviour
- Inspiration from endogenous biology — peptides derived from, or designed around, natural ligands, hormone sequences, or protein–protein interaction epitopes
- A validated or strongly supported molecular target implicated in a serious disease, with a credible route to in vitro and/or in vivo proof-of-concept

Disease areas of particular interest: oncology (PPI targets), inflammatory disorders, rare diseases with peptide-druggable mechanisms, CNS (where delivery solutions are integrated into the approach).

WHAT PEPDURA BRINGS TO A COLLABORATION

We contribute practical, hands-on drug development expertise across the translational arc, not advisory oversight, but active engagement:

- Lead optimisation and medicinal chemistry guidance (ADMET, selectivity, stability profiling)
- IND/CTA-enabling study design and operational management
- CMC and formulation strategy for peptide modalities
- Clinical study design and regulatory strategy through Phase 1/2
- Partnership structuring with larger pharmaceutical companies to fund and de-risk late-stage development

We also bring access to a network of specialist CROs, analytical laboratories, and regulatory consultants with peptide-specific experience.

COLLABORATION AND SPONSORSHIP TERMS — INDICATIVE FRAMEWORK

Collaboration structures are negotiated individually and with full involvement of your institution's TTO. Below is an indicative framework; actual terms will depend on stage, IP situation, and the scope of translational work agreed:

Structure	Typical Terms
Sponsored Research Agreement	Pepdura funds defined research milestones (typically PhD/postdoc FTE + consumables). Payment tranches tied to agreed scientific deliverables. Duration usually 12–24 months with renewal option.
Option-to-License	Pepdura obtains a time-limited exclusive option to negotiate a licence upon successful milestone completion. Low or no upfront payment; milestone payments and royalties on commercialisation. IP remains with the institution until licence is executed.

Co-development / JV	For more advanced technologies: shared development responsibilities, joint governance, and negotiated equity or revenue-share. Suitable where significant academic contribution continues beyond initial proof-of-concept.
EU consortium participation	For technologies suitable for Horizon Europe or EIC Pathfinder applications: Pepdura participates as industrial partner, supporting grant writing and contributing matching funding and in-kind expertise.

WHAT TO SUBMIT (NON-CONFIDENTIAL, ONE PAGE)

Please address the following in your submission:

- Technology title and a brief plain-language description
- Peptide origin and stabilisation strategy (in general terms)
- Target, pathway, and disease area
- Key biological evidence available (assay types, model systems; no raw data required)
- Current development stage and proposed next steps
- Publication and patent status (published only; general terms acceptable)
- Preferred collaboration model, if any

EVALUATION PROCESS

1. Submit your one-page summary to the contact below **no later than June 30, 2026**
2. Pepdura scientific review within four weeks; we will acknowledge receipt promptly
3. If of interest: mutual CDA, followed by in-depth scientific discussion
4. If proceeding: collaborative framework agreed with your TTO before any research begins

---

Submit to:

Kjell G Stenberg, Dr. Med. Sc.
Email: stenberg@pepdura.com
Phone: +46 7128 331 331